Document Detail


Natural honey and cardiovascular risk factors; effects on blood glucose, cholesterol, triacylglycerole, CRP, and body weight compared with sucrose.
MedLine Citation:
PMID:  18454257     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It has been found that honey ameliorates cardiovascular risk factors in healthy individuals and in patients with elevated risk factors. The present study investigated the effect of natural honey on total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triacylglycerole, C-reactive protein (CRP), fasting blood glucose (FBG), and body weight in overweight individuals. There were 55 patients, overweight or obese, who were randomly recruited into the study and assigned into two groups: control group (17 subjects) and experimental group (38 subjects). Patients in the control group received 70 g of sucrose daily for a maximum of 30 days and patients in the experimental group received 70 g of natural honey for the same period. In the control and experimental groups, body weight, body mass index, body fat weight, total cholesterol, LDL-C, HDL-C, triacylglycerole, FBG, and CRP were measured before treatment and at day 31 after the commencement of treatment. Results showed that honey caused a mild reduction in body weight (1.3%) and body fat (1.1%). Honey reduced total cholesterol (3%), LDL-C (5.8), triacylglycerole (11%), FBG (4.2%), and CRP (3.2%), and increased HDL-C (3.3%) in subjects with normal values, while in patients with elevated variables, honey caused reduction in total cholesterol by 3.3%, LDL-C by 4.3%, triacylglycerole by 19%, and CRP by 3.3% (p < 0.05). It is our conclusion that consumption of natural honey reduces cardiovascular risk factors, particularly in subjects with elevated risk factors, and it does not increase body weight in overweight or obese subjects.
Authors:
N Yaghoobi; Noori Al-Waili; M Ghayour-Mobarhan; S M R Parizadeh; Z Abasalti; Z Yaghoobi; F Yaghoobi; H Esmaeili; S M R Kazemi-Bajestani; R Aghasizadeh; Khelod Y Saloom; G A A Ferns
Related Documents :
19186967 - Periodontal status in subjects with hyperlipidemia.
1638777 - Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabet...
2507877 - Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambula...
3207437 - Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholestero...
2782237 - A long term study of the health status and performance of sows on different feed allowa...
10065687 - Effects of dilated cardiomyopathy on the diaphragm in the syrian hamster.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-04-20
Journal Detail:
Title:  TheScientificWorldJournal     Volume:  8     ISSN:  1537-744X     ISO Abbreviation:  ScientificWorldJournal     Publication Date:  2008  
Date Detail:
Created Date:  2008-05-05     Completed Date:  2008-05-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101131163     Medline TA:  ScientificWorldJournal     Country:  England    
Other Details:
Languages:  eng     Pagination:  463-9     Citation Subset:  IM    
Affiliation:
Heart and Vascular Research Center, Bu-Ali Research Institute, Mashhad University of Medical Science, Mashhad, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Blood Glucose / analysis*
Body Weight / drug effects*
C-Reactive Protein / analysis*
Cardiovascular Diseases / blood,  prevention & control
Cholesterol / blood*
Female
Honey*
Humans
Male
Middle Aged
Obesity / blood,  drug therapy*
Risk Assessment
Risk Factors
Treatment Outcome
Triglycerides / blood*
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Triglycerides; 57-88-5/Cholesterol; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Static T2w MRU in noncalcular urinary obstruction: comparison of its two techniques.
Next Document:  Vasoactive hormones and the diabetic kidney.